Summary:
The French company develops new approaches to isolate full-length and native membrane therapeutic targets with the highest purity levels. The company produces its own pipeline of medically relevant targets and uses its technology platform for other companies that need to identify, extract and purify membrane proteins. The company is looking for academic partners to prepare a joint proposal to apply for European funding.
Description:
The company has developed an approach that provides life science partners with the opportunity to work with high-quality and reliable targets or antigens, compatible with all applications and in all areas (human, animal and plant).
This includes developing antibodies and/or discovering drug candidates through structure-based drug design (X-ray and Cryogenic electron microscopy) or high-throughput screening assays.
The platform developed by the company also enables the formulation of new vaccines including against COVID-19.
The company is willing to further develop its technology by participating in a European call for proposal.
The following topics have been identified but the company is open to other topics where its technology could be useful:
- HORIZON-HLTH-2021-STAYHLTH-01-02 : ”Towards a molecular and neurobiological understanding of mental health and mental illness for the benefit of citizens and patients”
- HORIZON-HLTH-2022-DISEASE-06-02-two-stage : “Pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs”
- HORIZON-HLTH-2022-DISEASE-06-03-two-stage “Vaccines 2.0 – Developing the next generation of vaccines”
- HORIZON-HLTH-2022-DISEASE-06-04-two-stage “Development of new effective therapies for rare diseases”
Research or Technical cooperation agreement would be concluded between the French SME and academic partners
Type (e.g. company, R&D institution…), field of industry and Role of Partner Sought:
The SME is looking for academics and R&D institutions involved in target identification and membrane target validation (G protein-coupled receptors, ion channels, receptors, transporters and viral targets) in all therapeutic areas (oncology, Central nervous system diseases, cardiovascular diseases, infectious diseases, ....) and for all life science fields (human, animal, crop science). Ideally partner sought is participating or piloting a Horizon Europe proposal and open to work with new partners. Research cooperation or technical ccoperation agreement would drive the collaboration.
Stage of Development:
Already on the market
Comments Regarding Stage of Development:
The company already implements its platform for clients projects all over the world. As each target/antigen is different, the success for isolating/producing the target/antigen in a native and functional format ready to be used for drug discovery purposes is not guaranteed. But thanks to its patented technologies and know-how, the success rate of the company is around 75%.
The company is willing to further improve its platform by participating to a collaborative research/innovation project.
IPR Status:
Secret Know-how,Patent(s) applied for but not yet granted,Patents granted,Trade Marks,Exclusive Rights
Comments Regarding IPR Status:
The company owns 8 patent families and was ranked one of the most innovative companies among FrenchTech cluster (according to Forbes mag. in 2018 and 2019)
The company has participated to 28 international papers, mostly as corresponding author, including one paper with Roche Pharmaceuticals and one with Astrazeneca.
Moreover, the company holds several presentations each year in particular at Discovery on Targets (Boston) and at the Protein Engineering Summit (USA), alone or invited by their partners.
External code:
TOFR20210421001
